Courier Therapeutics

Courier Therapeutics

Biotechnology, 2450 Holcombe BLVD, Houston, Texas, 21205, United States, 1-10 Employees

couriertherapeutics.com

  • LinkedIn

phone no Phone Number: +12*********

Who is COURIER THERAPEUTICS

Courier Therapeutics is a biotechnology startup with a cytotoxic-lymphocyte targeting therapy platform, with a focus on making cancer-immunotherapy safer and more efficacious. Courier's f...

Read More

map
  • 2450 Holcombe BLVD, Houston, Texas, 21205, United States Headquarters: 2450 Holcombe BLVD, Houston, Texas, 21205, United States
  • 2015 Date Founded: 2015
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $250 Million to $500 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from COURIER THERAPEUTICS

Courier Therapeutics Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Courier Therapeutics

Answer: Courier Therapeutics's headquarters are located at 2450 Holcombe BLVD, Houston, Texas, 21205, United States

Answer: Courier Therapeutics's phone number is +12*********

Answer: Courier Therapeutics's official website is https://couriertherapeutics.com

Answer: Courier Therapeutics's revenue is $250 Million to $500 Million

Answer: Courier Therapeutics's SIC: 2836

Answer: Courier Therapeutics's NAICS: 541714

Answer: Courier Therapeutics has 1-10 employees

Answer: Courier Therapeutics is in Biotechnology

Answer: Courier Therapeutics contact info: Phone number: +12********* Website: https://couriertherapeutics.com

Answer: Courier Therapeutics is a biotechnology startup with a cytotoxic-lymphocyte targeting therapy platform, with a focus on making cancer-immunotherapy safer and more efficacious. Courier's first application of this targeting technology technology, CT101, is a first-in-class IL2R agonist which specifically activates the NK and CD8 T cells against cancer.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access